Search results for "heart Failure"

showing 10 items of 863 documents

Red blood cell distribution width: A marker of anisocytosis potentially associated with atrial fibrillation

2019

The incorporation of biomarkers in the actually used risk scores seem to be helpful for early identifying atrial fibrillation (AF) patients at higher risk. The aim of this critical review of the scientific literature is to investigate the potential clinical significance of red blood cell distribution width (RDW) in AF. A systematic electronic search was carried out to identify all articles describing an epidemiological association between RDW and AF in adult human populations. Data abstraction was conducted on a final number of 35 articles (13 cross-sectional, 12 prospective and 10 retrospective studies). The results of these epidemiological investigations were all virtually concordant to e…

medicine.medical_specialtyErythrocytesRed blood cell distribution width RDW anisocytosis atrial fibrillationReview030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRed blood cell distribution widthInternal medicineEpidemiologyMedicineRDWClinical significanceatrial fibrillation030212 general & internal medicineanisocytosisbusiness.industryRetrospective cohort studyRed blood cell distribution widthAtrial fibrillationmedicine.diseaseThrombosisHeart failureCardiologyAnisocytosisCardiology and Cardiovascular MedicinebusinessArrhythmia
researchProduct

013 Pre-infarction angina and cardiovascular complications in non ST segment elevation myocardial infarction: Data from the RICO survey

2010

BackgroundThe presence of preinfarction angina (PIA) has been shown to confer cardioprotection after ST segment elevation myocardial infarction (MI). However, the impact of PIA in non ST segment elevation (NSTEMI) remains to be determined.Patients and MethodsFrom the obseRvatoire des Infarctus de Côte d’Or (RICO) survey, 1541 consecutive patients admitted in intensive care unit with a first NSTEMI were included in the study. Patients who experienced chest pain 1) and 30-day mortality were collected.ResultsAmong the 1541 patients included in the study, 693 patients presented PIA. Baseline clinical characteristics were similar for the 2 groups. There was no significant difference for the GRAC…

medicine.medical_specialtyFramingham Risk Scorebusiness.industryInfarctionmedicine.diseaseChest painIntensive care unitlaw.inventionAnginalawHeart failureInternal medicinemedicineCardiologyST segmentMyocardial infarctionmedicine.symptomCardiology and Cardiovascular MedicinebusinessArchives of Cardiovascular Diseases Supplements
researchProduct

Clinical Role of CA125 in Worsening Heart Failure

2020

Abstract Objectives The aim of this study was to evaluate the association between antigen carbohydrate 125 (CA125) and the risk of 1-year clinical outcomes in patients with worsening heart failure (HF). Background CA125 is a widely available biomarker that is up-regulated in patients with acute HF and has been postulated as a useful marker of congestion and risk stratification. Methods In a large multicenter cohort of patients with worsening HF, either in-hospital or in the outpatient setting, the independent associations between CA125 and 1-year death and the composite of death/HF readmission (adjusted for outcome-specific prognostic risk score [BIOSTAT risk score]) were determined by usin…

medicine.medical_specialtyFramingham Risk Scoreendocrine system diseasesbusiness.industrymedicine.drug_class030204 cardiovascular system & hematologymedicine.diseaseTailored treatmentfemale genital diseases and pregnancy complications03 medical and health sciences0302 clinical medicineIncreased riskHeart failureInternal medicineCohortmedicineNatriuretic peptideBiomarker (medicine)In patient030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessJACC: Heart Failure
researchProduct

Fibrosis markers and CRIM1 increase in chronic heart failure of increasing severity.

2014

AbstractBackground: Fibrosis suppressors/activators in chronic heart failure (CHF) is a topic of investigation.Aim: To quantify serum levels of fibrosis regulators in CHF.Methods: ELISA tests were used to quantify fibrosis regulators, procollagen type-(PIP)I, (PIP)III, collagen-I, III, BMP1,2,3,7, SDF1α, CXCR4, fibulin 1,2,3, BMPER, CRIM1 and BAMBI in 66 CHF (NYHA class I, n = 9; II, n = 34; III n = 23), and in 14 controls.Results: In CHF, TGFβR2, PIPIII, SDF1α and CRIM1 were increased. PIPIII correlated with CRIM1.Conclusions: The BMPs inhibitor CRIM1 is increased and correlates with higher levels of serum PIPIII showing an imbalance in favor of pro-fibrotic mechanisms in CHF.

medicine.medical_specialtyHealth Toxicology and MutagenesisClinical BiochemistryInflammationBiochemistryGastroenterologySeverity of Illness IndexBone morphogenetic protein 1ElectrocardiographyFibrosisInternal medicinemedicineEndothelial dysfunction heart fibrosis inflammationHumanscardiovascular diseasesEndothelial dysfunctionHeart Failurebusiness.industryMembrane ProteinsBone Morphogenetic Protein Receptorsmedicine.diseaseFibulinProcollagen peptidaseHeart failureImmunologyChronic Diseasecardiovascular systemBAMBImedicine.symptombusinesscirculatory and respiratory physiology
researchProduct

Non-Hemodynamic Effects of Organic Nitrates and the Distinctive Characteristics of Pentaerithrityl Tetranitrate

2009

Organic nitrates are among the oldest and yet most commonly employed drugs in the long-term therapy of coronary artery disease and congestive heart failure. While they have long been used in clinical practice, our understanding of their mechanism of action and side effects remains incomplete. For instance, recent findings provide evidence of previously unanticipated, non-hemodynamic properties that include potentially beneficial mechanisms (such as the induction of a protective phenotype that mimics ischemic preconditioning), but also toxic effects (such as endothelial and autonomic dysfunction, rebound angina, tolerance). To date, the most commonly employed organic nitrates are isosorbide …

medicine.medical_specialtyHeart DiseasesVasodilator AgentsIsosorbide DinitratePharmacologyDrug Administration ScheduleAnginaCoronary artery diseaseNitroglycerinmedicineIsosorbide mononitrateAnimalsHumansPentaerythritol TetranitratePharmacology (medical)NitroglycerinNitratesbusiness.industryDrug ToleranceGeneral Medicinemedicine.diseaseSurgeryEastern europeanOxidative StressHeart failureIschemic preconditioningIsosorbide dinitrateReactive Oxygen SpeciesCardiology and Cardiovascular Medicinebusinessmedicine.drugAmerican Journal of Cardiovascular Drugs
researchProduct

Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study…

2021

AbstractAimsPatients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality.Method and resultsWe used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existent heart disease and in-hospital mortality. 16,511 patients with COVID-19 were included (21.1% aged 66 – 75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male and of…

medicine.medical_specialtyHeart diseaseCoronavirus disease 2019 (COVID-19)business.industryDiseasemedicine.diseasesymbols.namesakeHeart failureInternal medicineRelative riskmedicinesymbolsPoisson regressionPresentation (obstetrics)businessCohort study
researchProduct

The role of statins in preventing the progression of congestive heart failure in patients with metabolic syndrome.

2008

Heart Failure (CHF) is a very important public health problem in the world and certainly one of the most common debilitating diseases and cause of mortality. Current knowledge underlines that incidence rates are also influenced by the coexisting pathologic conditions that accelerate the development of disease or increase its severity. Important scientific evidence is emerging to demonstrate a strong correlation between HF and the metabolic syndrome (MetS). Hypolipemia- inducing medication offers the opportunity to discuss the possible existence of pharmacological substances that in addition to their specific targets have several demonstrated pleiotropic effects that could be beneficial in H…

medicine.medical_specialtyHeart diseaseDiseaseBioinformaticsstatin congestive heart failure metabolic sydromeHypolipemiaInternal medicineDrug DiscoverymedicineAnimalsHumansIn patientPharmacologyHeart FailureMetabolic SyndromeClinical Trials as Topicbusiness.industryPublic healthmedicine.diseaseOxidative StressEndocrinologyHeart failureDisease ProgressionMetabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCurrent pharmaceutical design
researchProduct

The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS

2008

Atrial fibrillation (AF) is the most common rhythm disturbance in medical practice and represents a very expensive health problem. AF can be managed with the prevention of thromboembolism and either a rate control of rhythm strategy. As both strategies have important limitations, probably a preventative strategy in patients at risk of developing arrhythmia can be a more attractive option. The renin-angiotensin system (RAS) seems to be involved in the genesis of arrhythmia by the following two mechanisms: 1. the induction of atrial fibrosis and structural remodelling by mitogen-activated protein kinase (MAPK) expression and reduction of collagenase activity; 2. the induction of electrical re…

medicine.medical_specialtyHeart diseaseGenotypeElectric CountershockAngiotensin-Converting Enzyme InhibitorsReview ArticleRenin-Angiotensin Systemrenin-angiotensin system atrial fibrillation ACE-I ARBDiabetes mellitusInternal medicineRenin–angiotensin systemAtrial FibrillationmedicineHumansPharmacology (medical)PharmacologyMitogen-Activated Protein Kinase KinasesEvidence-Based Medicinebiologybusiness.industryAngiotensin IIfungifood and beveragesAtrial fibrillationAngiotensin-converting enzymemedicine.diseaseAngiotensin IIEndocrinologyHeart failureACE inhibitorCardiologybiology.proteinbusinessAnti-Arrhythmia Agentsmedicine.drug
researchProduct

Covid-19 and Congenital Heart Disease: results from a nationwide survey

2020

Background. The pandemic of Novel Coronavirus Disease 2019 (COVID-19) is challenging, given the large number of hospitalized patients. Cardiovascular co-morbidities are linked to a higher mortality risk. Thus, patients with Congenital Heart Disease (CHD) might represent a high-risk population. Nevertheless, no data about them are available, yet. Hence, we conducted a nationwide survey to assess clinical characteristics and outcomes in patients with congenital heart disease affected by COVID-19. Methods and Results. This is a multi-centre, observational, nationwide survey, involving high-volume Italian CHD centres. COVID-19 diagnosis was defined as either &ldquo

medicine.medical_specialtyHeart diseasePopulationcardiovascular complicationslcsh:Medicine030204 cardiovascular system & hematologyChest painArticle03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinecongenital heart disease COVID-19 cardiovascular complicationsmedicinePalpitations030212 general & internal medicineeducationStrokecardiovascular complicationeducation.field_of_studybusiness.industrylcsh:Rcongenital heart disease; COVID-19; cardiovascular complicationsCOVID-19General Medicinemedicine.diseasecongenital heart diseaseHeart failureCohortmedicine.symptombusiness
researchProduct

Treatment and Prophylaxis

1991

Following a stroke, the patient’s neurologic deficit may be most impressive, but his treatment and prognosis depend largely upon accompanying systemic disorders. Acute treatment, for instance, must take into consideration such things as cardiovascular disorders (myocardial infarction, valve defects, arrhythmias, hypertension), disorders of renal function, and diabetes mellitus. The early detection and treatment of such systemic problems can help to prevent complications that would be difficult to control later. Thus, in a patient with latent heart disease hypervolemic therapy with low molecular weight dextran may in fact elicit right heart failure and pulmonary edema instead of helping the …

medicine.medical_specialtyHeart diseasebusiness.industryCerebral infarctionRenal functionmedicine.diseasePulmonary edemaLow molecular weight dextranRight heart failureDiabetes mellitusInternal medicinemedicineCardiologyMyocardial infarctionbusiness
researchProduct